{Reference Type}: Journal Article
{Title}: Exploring the Neuroinflammatory Pathway in Epilepsy and Cognitive Impairment: Role of HMGB1 and Translational Challenges.
{Author}: Ngadimon IW;Seth EA;Shaikh MF;
{Journal}: Front Biosci (Landmark Ed)
{Volume}: 29
{Issue}: 6
{Year}: 2024 Jun 24
{Factor}: 3.115
{DOI}: 10.31083/j.fbl2906229
{Abstract}: Neuroinflammation has emerged as a shared molecular mechanism in epilepsy and cognitive impairment, offering new insights into the complex interplay between immune responses and brain function. Evidence reveals involvement of High mobility group box 1 (HMGB1) in blood-brain barrier disruption and correlations with epilepsy severity and drug resistance. While anti-inflammatory treatments show promise, translating these discoveries faces challenges in elucidating mechanisms and developing reliable biomarkers. However, strategically targeting neuroinflammation and HMGB1-mediated inflammation holds therapeutic potential. This review synthesises knowledge on HMGB1 and related biomarkers in epilepsy and cognitive impairment to shape future research and treatments targeting these intricate inflammatory processes.